Exploring the Interaction of MDM2 and p53 in Soft Tissue Sarcomas

Publication
Article
Supplements and Featured PublicationsDiagnosis and Trial Options in Sarcoma
Volume 1
Issue 1

Articles in this issue
Javier Martin-Broto, MD, PhD,
Dr. Martin-Broto on Future Research Directions of Soft Tissue Sarcoma
Exploring the Interaction of MDM2 and p53 in Soft Tissue Sarcomas
Exploring the Interaction of MDM2 and p53 in Soft Tissue Sarcomas
Jean-Yves Blay, MD
Dr. Blay on Treatment Considerations in Soft Tissue Sarcomas
Patricia LoRusso, DO
Dr. LoRusso on the Benefit of Genetic Sequencing in Sarcomas
Javier Martin-Broto, MD, PhD
Dr. Martin-Broto on the Current First-Line Treatment of Soft Tissue Sarcomas
Javier Martin-Broto, MD, PhD
Dr. Martin-Broto on MDM2 and P53 in Soft Tissue Sarcoma
Javier Martin-Broto, MD, PhD
Dr. Martin-Broto on the Ongoing Research of MDM2 Agonists in Soft Tissue Sarcoma
Patricia LoRusso, DO
MDM2 Pulls Novel Treatments Into Focus for Underserved Liposarcoma Population
Patricia LoRusso, DO
Dr. LoRusso on the Importance of Clinical Trials in MDM2-Amplified Dedifferentiated Liposarcoma
Jean-Yves Blay, MD
Dr. Blay on the Current Treatment Challenges in Soft Tissue Sarcomas
Patricia LoRusso, DO
Dr. LoRusso on the Efficacy of BI 907828 in Solid Tumors
Jean-Yves Blay, MD
Dr. Blay on the Exploration of BI 907828 in Patients With Sarcoma
Related Videos
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Elias Jabbour, MD
Shruti Tiwari, MD
Video 5 - "AE Management with CDK4/6 Inhibitors: Strategies for Treatment Continuity and Optimal Patient Outcomes"
Jeffrey P. Townsend, PhD
Marina Baretti, MD
Related Content
Heinz-Josef Lenz, MD, University of Southern California Norris Comprehensive Cancer Center

Retrospective Data Show Association Between HER2 Expression and Survival Outcomes in mCRC

April 25th 2024
Article
Saad Z. Usmani, MD, MBA, FACP, FASCO, hematologist-oncologist, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center

FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy

April 22nd 2024
Podcast
He Huang, MD, PhD, of First Affiliated Hospital, Zhejiang University School of Medicine

CD7 CAR T-Cell Therapy Plus Allogeneic HSCT Is Safe, Feasible in CD7+ Hematologic Malignancies

April 24th 2024
Article
Matthew Lunning, DO, FACP, associate professor, Division of Oncology & Hematology, associate vice chair, research, Department of Internal Medicine, assistant vice chancellor, clinical research, University of Nebraska Medical Center; Sarah Rutherford, MD, assistant professor, medicine, Division of Hematology/Oncology, Weill Cornell Medicine

Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma

April 18th 2024
Podcast
stock.adobe.com

Eftilagimod Alpha Plus Pembrolizumab Elicits Early Efficacy Signals in Metastatic HNSCC

April 24th 2024
Article
George Zogopoulos, MD, PhD, McGill University Health Centre

International Pancreatic Cancer Screening Program Displays Practicality

April 24th 2024
Article